A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Identifieur interne : 001A64 ( PubMed/Corpus ); précédent : 001A63; suivant : 001A65A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Auteurs : Kia Schulze ; Caroline Staib ; Hermann M. Sch Tzl ; Thomas Ebensen ; Volker Erfle ; Carlos A. GuzmanSource :
- Vaccine [ 0264-410X ] ; 2008.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Administration, Intranasal, Animals, Antibodies, Viral (immunology), Immunity, Cellular, Immunization, Secondary (methods), Immunoglobulin A (immunology), Injections, Intramuscular, Lipopeptides (immunology), Mice, Mice, Inbred BALB C, Nucleocapsid Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Vaccinia virus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , immunology : Antibodies, Viral, Immunoglobulin A, Lipopeptides, Nucleocapsid Proteins, Viral Vaccines.
- chemical : Adjuvants, Immunologic.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Vaccinia virus.
- methods : Immunization, Secondary.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Immunity, Cellular, Injections, Intramuscular, Mice, Mice, Inbred BALB C.
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
DOI: 10.1016/j.vaccine.2008.09.006
PubMed: 18805454
Links to Exploration step
pubmed:18805454Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.</title><author><name sortKey="Schulze, Kia" sort="Schulze, Kia" uniqKey="Schulze K" first="Kia" last="Schulze">Kia Schulze</name><affiliation><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name></author><author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M" last="Sch Tzl">Hermann M. Sch Tzl</name></author><author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name></author><author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name></author><author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzman">Carlos A. Guzman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18805454</idno><idno type="pmid">18805454</idno><idno type="doi">10.1016/j.vaccine.2008.09.006</idno><idno type="wicri:Area/PubMed/Corpus">001A64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.</title><author><name sortKey="Schulze, Kia" sort="Schulze, Kia" uniqKey="Schulze K" first="Kia" last="Schulze">Kia Schulze</name><affiliation><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name></author><author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M" last="Sch Tzl">Hermann M. Sch Tzl</name></author><author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name></author><author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name></author><author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzman">Carlos A. Guzman</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Immunity, Cellular</term><term>Immunization, Secondary (methods)</term><term>Immunoglobulin A (immunology)</term><term>Injections, Intramuscular</term><term>Lipopeptides (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Nucleocapsid Proteins (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Vaccinia virus (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin A</term><term>Lipopeptides</term><term>Nucleocapsid Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vaccinia virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Secondary</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Immunity, Cellular</term><term>Injections, Intramuscular</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18805454</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>51</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.</ArticleTitle><Pagination><MedlinePgn>6678-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2008.09.006</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulze</LastName><ForeName>Kia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staib</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schätzl</LastName><ForeName>Hermann M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Ebensen</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Erfle</LastName><ForeName>Volker</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055666">Lipopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>DZX5IUA94D</RegistryNumber><NameOfSubstance UI="C106335">macrophage stimulatory lipopeptide 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055666" MajorTopicYN="N">Lipopeptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014616" MajorTopicYN="N">Vaccinia virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>02</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18805454</ArticleId><ArticleId IdType="pii">S0264-410X(08)01215-2</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2008.09.006</ArticleId><ArticleId IdType="pmc">PMC7115531</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>BMJ. 2003 Apr 19;326(7394):850-2</Citation><ArticleIdList><ArticleId IdType="pubmed">12702616</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Jun 20;300(5627):1961-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12766206</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Aug;77(15):8394-407</Citation><ArticleIdList><ArticleId IdType="pubmed">12857909</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhonghua Nei Ke Za Zhi. 2003 Sep;42(9):643-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14514395</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2269-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15755609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Dec;81(24):13365-77</Citation><ArticleIdList><ArticleId IdType="pubmed">17913799</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2003 Feb;84(Pt 2):361-368</Citation><ArticleIdList><ArticleId IdType="pubmed">12560568</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S9-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15018127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2007 Jul 5;363(2):288-302</Citation><ArticleIdList><ArticleId IdType="pubmed">17331558</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Feb;3(2):e27</Citation><ArticleIdList><ArticleId IdType="pubmed">16379499</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Agent Cancer. 2007 Jul 10;2:14</Citation><ArticleIdList><ArticleId IdType="pubmed">17623060</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 Aug 28;24(35-36):6088-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16828529</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Avian Pathol. 2003 Dec;32(6):567-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14676007</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cancer Res. 2003 Nov 15;63(22):7942-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14633725</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Exp Med Biol. 1995;380:221-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8830483</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Lett. 2004 Sep;95(2):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2005 Jan;86(Pt 1):211-215</Citation><ArticleIdList><ArticleId IdType="pubmed">15604448</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 2002 Oct;32(10):2857-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12355438</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Jan 5;331(1):128-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15582659</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2004 Apr 22;350(17):1731-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15102999</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chin Med J (Engl). 2003 Sep;116(9):1283-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14527349</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2007 Sep 1;179(5):2797-807</Citation><ArticleIdList><ArticleId IdType="pubmed">17709493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 1998 Mar;28(3):1069-77</Citation><ArticleIdList><ArticleId IdType="pubmed">9541603</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2008 Feb 8;376(1):23-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18155731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S20-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15018129</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1997 Oct;71(10):7889-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9311878</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Jul 16;290(3):374-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12865379</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2006 Mar;87(Pt 3):641-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16476986</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1993 Oct;74 ( Pt 10):2061-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8409930</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(8):3930-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15047809</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Appl Microbiol Biotechnol. 2005 Aug;68(2):220-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15660214</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Mol Med. 2003;87:51-68</Citation><ArticleIdList><ArticleId IdType="pubmed">12958449</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 Mar 15;24(12):2049-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16406225</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pneumologie. 2007 Oct;61(10):663-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17763311</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001A64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:18805454
|texte= A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18805454" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |